InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.00%
)
Bitcoin
68,990.82
(
-0.40%
)
Post# of 251939
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119690
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jbog post# 217266

Wednesday, 02/14/2018 8:14:52 AM

Wednesday, February 14, 2018 8:14:52 AM

Post# of 251939
NKTR-214 is absolutely worth the price BMY is paying, IMO. Anecdotal info from the Opdivo/NKTR-214 sarcoma IST has some patients with Stage-IV disease obtaining long-lasting responses. NKTR has cited this trial as a possible quick path to FDA approval due to the unmet medical need in sarcoma.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up